The Tufts Center for Drug Development issues its annual assessment of the state of R&D in Big Pharma, noting that industry faces a cumulative tide of challenges marked by a dramatic reversal in societal attitudes toward risk. Productivity gaps in the pipeline aside, perhaps the biggest problem is political — convincing stakeholders to strive for [...]
PharmExec Blog
Follow Us
RSS
Bookstore
Tufts R&D Outlook for 2011: Pain Mixed with Promise